Clone emergence and evolution in chronic lymphocytic leukemia: Characterization of clinical, laboratory and immunophenotypic profiles of 25 patients

Leukemia and Lymphoma

Volumn 6, Issue 4-5, 1992, Pages 345-356

  Faguet, Guy B ^a,b,c   Agee, Julia F ^a,b   Marti, Gerald E ^d  

^a Cancer Immunology Research Laboratory ^*  (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

B CLL; Clonal evolution in CLL; Clone emergence; Immunophenotype

Indexed keywords

CD5 ANTIGEN; LEUKEMIA ANTIGEN; LYMPHOCYTE ANTIGEN; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; CANCER DIAGNOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLONE; CLONOGENESIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRELEUKEMIA;

EID: 0026596273     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199209053566     Document Type: Article

References (48)

1. Clinical staging of chronic lymphocytic leukemia
2. Chronic lymphocytic leukemia: Proposal for a revised prognostic staging system
3. Immunophenotypic diagnosis of clinical and preclinical chronic lymphatic leukemia by using monoclonal antibodies against the cCLLa, a CLL-associated antigen
4. Recommendations for Diagnosis, Staging and Response criteria
5. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group
6. An antigen common to chronic lymphocytic and hairy cell leukemia cells not shared by normal lymphocytes nor by other leukemia cells
7. Monoclonal antibodies against the chronic lymphatic leukemia antigen, cCLLa: Characterization and reactivity
8. Modulation, shedding and serum titers of the chronic lymphatic leukemia-associated antigen (cCLLa): Characterization and clinical correlations
9. Common chronic lymphatic leukemia antigen (cCLLa); Distribution, fate and clinical applications
10. Lymphocyte purification, an improved method: Qualitative and quantitative evaluation
11. Cytochemical, cytogenetic, immunophenotypic and tumori-genic characterization of two hairy cell lines
12. Smudged Cells in Lymphocytic Leukemia
13. The CD5 B-cells
14. Production of Autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia
15. Evidence that CLL B-lymphocytes are frequently committed for the production of multispecific autoantibodies
16. Rheumatoid factor secretion from human leu-1 + B cells
17. B cells expressing CD5 are increased in Sjogren's syndrome
18. Phenotype of recovering lymphoid cell populations after marrow transplantation
19. Surface bound immunoglobulins as a cell marker in human lymphoprolifera-tive diseases
20. Cell surface immunoglobulin in chronic lymphocytic leukemia and allied disorders
21. Mouse red blood cell rosettes in B lymphoproliferative disorders
22. Surface markers in chronic lymphoid leukemias of B cell type
23. Identification of p69,71 complex expressed on human T cells sharing determinants with B type chronic lymphocytic cells
24. Human T-cell antigens defined by monoclonal antibodies: The 65,000 dalton antigen to T-cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulins
25. Cell cycle dependent expression of the common chronic lymphocytic leukemia antigen (cCLLa)
26. Chronic Lymphocytic Leukemia: When and How to Treat
27. Critical factors in new thearapeutic approaches in chronic lymphocytic leukemia (CLL)
28. Comparison of the A, B, C staging and the Rai's staging from a large prospective series (935 patients)
29. Natural history of stage A-chronic lymphocytic leukemia (CLL). Delineation of patients not requiring early treatment. A study from 309 patients
30. Therapy of chronic lymphocytic leukemia patients. Results from the French cooperative trials
31. Fludarabine monophosphate: a potential useful agent in chronic lymphocytic leukemia
32. Fludarabine therapy in chronic lymphocytic leukemia (CLL)
33. Purine metabolism as a target for leukemia chemotherapy
34. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia
35. The fourth modality of cancer treatment
36. Biological response modifiers: Their potential and limitations in cancer therapeutics
37. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group Pilot Study
38. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia-A pilot study
39. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia
40. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia
41. A clinical trial of anti-idiotype therapy for B cell malignancy
42. Redesigning nature's poisons to create anti-tumor reagents
43. A phase 1 study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia
44. Kinetics of the malignant clone during fludarabine treatment of chronic lymphatic leukemia (CLL)
45. Biological response modifiers for the therapy of cancer
46. vitro evaluation of a ricin A chain-based immunotoxin directed against the common chronic lymphocytic leukemia antigen (cCLLa): A potential biological agent for in vivo therapy
47. Deglycosylated ricin A chain-based immunotoxin directed against the common chronic lymphocytic antigen (cCLLa): in vitro specificity and cytotoxic activity